| OCREVUS Access Solutions may be able to help |
| OCREVUS Access Solutions offers a range of coverage and reimbursement support options for your patients and practice. |
| Follow these steps to help your patients access OCREVUS. |
|
|
|
| Obtain any necessary prior authorizations |
| OCREVUS Access Solutions can help identify if a prior authorization is necessary and offer resources as you obtain it for your patient. |
|
|
| Determine your patient’s out-of-pocket costs and whether patient assistance is needed |
| Determine which patient assistance option is right for your patient with the Patient Assistance Tool. |
|
|
| Acquire OCREVUS via buy and bill or a specialty pharmacy (SP) |
| See a list of authorized distributors and specialty pharmacies. |
|
|
| Submit a claim for reimbursement |
| OCREVUS Access Solutions can provide reimbursement resources such as sample coding information, tips for billing and resources for denials and appeals, if needed. |
|
|
| To learn more, visit OCREVUS.com, or contact your OCREVUS Clinical Specialist directly. |
|
| Indication |
| OCREVUS is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis. |
| Contraindications |
| OCREVUS is contraindicated in patients with active hepatitis B virus infection and in patients with a history of life-threatening infusion reaction to OCREVUS. |
| Warnings and Precautions |
| Infusion reactions: |
| Management recommendations for infusion reactions depend on the type and severity of the reaction. Permanently discontinue OCREVUS if a life-threatening or disabling infusion reaction occurs. |
| Infections: |
| Delay OCREVUS administration in patients with an active infection until the infection is resolved. Vaccination with live-attenuated or live vaccines is not recommended during treatment with OCREVUS and after discontinuation, until B-cell repletion. |
| Malignancies: |
| An increased risk of malignancy, including breast cancer, may exist with OCREVUS. |
| Most Common Adverse Reactions |
| RMS: The most common adverse reactions (≥10% and >REBIF): upper respiratory tract infections and infusion reactions. |
| PPMS: The most common adverse reactions (≥10% and >placebo): upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections. |
| For additional safety information, please see the full Prescribing Information and Medication Guide. |
|
|
|
|
